Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,815.00GBp
18 Apr 2019
Change (% chg)

-99.00 (-1.67%)
Prev Close
5,914.00
Open
5,860.00
Day's High
5,894.00
Day's Low
5,806.00
Volume
2,072,049
Avg. Vol
2,159,464
52-wk High
6,540.00
52-wk Low
4,928.50

Latest Key Developments (Source: Significant Developments)

US FDA Approves Circassia Pharma and AstraZeneca's Duaklir Pressair For Patients With COPD
Wednesday, 17 Apr 2019 

April 17 (Reuters) - AstraZeneca PLC ::US FOOD AND DRUG ADMINISTRATION APPROVES DUAKLIR® PRESSAIR® (ACLIDINIUM/FORMOTEROL) FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).CIRCASSIA PHARMACEUTICALS PLC - U.S. FDA APPROVES DUAKLIR PRESSAIR FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.CIRCASSIA PHARMACEUTICALS PLC - ONLY TWICE-DAILY LAMA /LABA IN U.S. WITH COPD EXACERBATION DATA INCLUDED IN ITS PRESCRIBING INFORMATION.  Full Article

Astrazeneca Says Lynparza Approved In EU For Treatment Of Germl
Wednesday, 10 Apr 2019 

April 10 (Reuters) - AstraZeneca PLC ::LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERML.LYNPARZA APPROVED IN EU FOR TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE ADVANCED BREAST CANCER.  Full Article

AstraZeneca ABO: Bookrunner Says Price Guidance To Follow At Around 3PM UK
Friday, 29 Mar 2019 

March 29 (Reuters) - BOOKRUNNER On ASTRAZENECA PLC ABO::ASTRAZENECA PLC ABO: BOOKRUNNER SAYS PRICE GUIDANCE TO FOLLOW AT AROUND 3.00PM UK POST UK PARLIAMENTARY VOTE.ASTRAZENECA PLC ABO: BOOKRUNNER SAYS BOOKS REMAINS WELL COVERED, ALLOCATIONS EXPECTED TO BE OUT PRE MARKET CLOSE.  Full Article

Astrazeneca Says Forxiga Approved In Japan For Type-1 Diabetes
Wednesday, 27 Mar 2019 

March 27 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES.ASTRAZENECA - JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE APPROVED FORXIGA AS ORAL ADJUNCT TREATMENT TO INSULIN FOR ADULTS WITH TYPE-1 DIABETES.  Full Article

Astrazeneca's Forxiga Gets EU Approval For Type-1 Diabetes Treatment
Monday, 25 Mar 2019 

March 25 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - APPROVED IN EUROPE FOR TYPE-1 DIABETES.ASTRAZENECA PLC - EC HAS APPROVED FORXIGA FOR USE IN TYPE-1 DIABETES (T1D) AS AN ADJUNCT TO INSULIN IN PATIENTS WITH A BMI ≥ 27 KG/M(2).  Full Article

US FDA Approves Expanded Farxiga And Xigduo XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - AstraZeneca PLC ::US FDA APPROVES EXPANDED FARXIGA AND XIGDUO XR LABELS FOR USE IN PATIENTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT.ASTRAZENECA PLC - UPDATED LABEL CONFIRMS WELL-ESTABLISHED EFFICACY AND SAFETY PROFILE FOR FARXIGA AND XIGDUO XR.ASTRAZENECA PLC - US FDA APPROVES EXPANDED FARXIGA AND XIGDUO XR LABELS FOR USE IN PATIENTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT.  Full Article

AstraZeneca Says It Has Additional Stock Build Of 6 Weeks In UK In Preparation For Brexit
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - AstraZeneca PLC ::ASTRAZENECA SAYS TAGRISSO IS ON TRACK TO BE THE BIGGEST DRUG FOR CO IN 2019 - CONF CALL.ASTRAZENECA SAYS EMERGING MARKETS CONTINUE TO TRACK AHEAD OF LONG TERM TARGETS - CONF CALL.ASTRAZENECA, ON BREXIT, SAYS TAKEN STEPS TO SAFEGUARD PATIENT ACCESS TO MEDICINES; ADDITIONAL FINISHED-PACK STOCK BUILD OF 6 WEEKS IN UK, 4 WEEKS IN EU.ASTRAZENECA, ON HEARING RELATED TO U.S. DRUG PRICING, SAYS "WE WELCOME THE HEARING SO WE CAN ENGAGE IN CONSTRUCTIVE DIALOGUE" .  Full Article

Active Biotech Partner NeoTX Enters Clinical Collaboration With AstraZeneca
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Active Biotech Ab ::REG-ACTIVE BIOTECH'S PARTNER NEOTX ENTERS CLINICAL COLLABORATION WITH ASTRAZENECA TO EVALUATE ANYARA IN COMBINATION WITH IMFINZI® (DURVALUMAB) IN THE UPCOMING PHASE 1B/2 STUDY.NEOTX WILL SPONSOR STUDY, WHILE ASTRAZENECA WILL SUPPLY DURVALUMAB.UNDER TERMS OF AGREEMENT, NEOTX AND ASTRAZENECA WILL COLLABORATE ON A NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN SOLID TUMORS.NEOTX WILL SPONSOR STUDY, WHILE ASTRAZENECA WILL SUPPLY DURVALUMAB.  Full Article

Senate Finance Committee's Grassley, Wyden Invite 7 Pharmaceutical Companies to Drug Pricing Hearing
Tuesday, 5 Feb 2019 

Feb 4 (Reuters) - United States Senate Committee on Finance::U.S. SENATE COMMITTEE ON FINANCE - CHAIRMAN CHUCK GRASSLEY, RANKING MEMBER RON WYDEN INVITED 7 PHARMACEUTICAL COS TO A FEB. 26 DRUG PRICING HEARING.U.S. SENATE COMMITTEE ON FINANCE - COS INVITED TO FEB. 26 DRUG PRICING HEARING INCLUDE ABBVIE, ASTRAZENECA, BRISTOL-MYERS SQUIBB, JOHNSON & JOHNSON.U.S. SENATE COMMITTEE ON FINANCE - COS INVITED TO FEB. 26 DRUG PRICING HEARING ALSO INCLUDE MERCK & CO, PFIZER AND SANOFI.  Full Article

UPMC Health Plan Announces Value-Based Agreement With AstraZeneca For BRILINTA Coverage
Monday, 28 Jan 2019 

Jan 28 (Reuters) - UPMC Health Plan::UPMC HEALTH PLAN - CO, ASTRAZENECA INITIATE VALUE-BASED CONTRACT EFFECTIVE JAN. 1 FOR UPMC FOR LIFE MEDICARE MEMBERS PRESCRIBED BRILINTA (TICAGRELOR).  Full Article

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: